Idiopathic Pulmonary Fibrosis and Serum Bank
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 903
- 试验地点
- 1
- 主要终点
- Determination of circulating CD163 serum concentration
研究概览
简要总结
Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults. It is a fibroproliferative, irreversible disease of unknown cause, usually progressive, occurring mainly from the age of 60 and limited to the lungs. IPF is a serious disease with a median survival rate at diagnosis of 3 years.
The aim of the study is to set up a biocollection of serum from patients in a context of idiopathic DILD and a possible or confirmed diagnosis of common interstitial lung disease by chest CT.
Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
详细描述
This study will initially focus on circulating serum CD163 markers, but a broader proteomics approach could be considered in a second phase to look for other markers of lung diseases.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients seen on an outpatient basis and in stable or acute condition
- •Patient over 18 years of age.
- •The inclusion criteria will be those edited by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) to diagnosis IPF
排除标准
- •Patients who are unable or unwilling to sign the consent.
结局指标
主要结局
Determination of circulating CD163 serum concentration
时间窗: Through study completion, an average of 4 years
Serum CD163 levels in patients with possible or certain DILD will be performed by ELISA technique (R\&D Systems kit, Minneapolis, MN).
次要结局
未报告次要终点